查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606869

促紅血球生成素興奮劑市場：按類型、按應用分類 - 全球預測 2025-2030

Erythropoietin Stimulating Agents Market by Type (Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta), Application (Anemia, Antiretroviral Treatment, Cancer Chemotherapy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年促紅血球生成素興奮劑市值為98.4億美元，預計2024年將達到103.2億美元，複合年成長率為5.64%，預計到2030年將達到144.5億美元。

促紅血球生成素 (ESA) 是一種生物工程藥物，用於刺激紅血球生成，主要用於因慢性腎臟病、癌症治療或某些慢性疾病而患有貧血的患者。這些藥物，包括阿法依泊汀和Darbepoetin汀，透過減少輸血需求在醫療中發揮重要作用。 ESA 的需求和範圍擴展到末期腎臟病的貧血管理，並且擴大在非透析依賴性慢性腎臟病和其他貧血相關疾病中進行研究。市場終端用途多種多樣，包括醫院、診所和門診手術中心。

主要市場統計
基準年[2023] 98.4億美元
預測年份 [2024] 103.2億美元
預測年份 [2030] 144.5億美元
複合年成長率（%） 5.64%

慢性病盛行率上升、人口老化和生技藥品需求增加推動了市場成長。此外，對具有更高效率和安全性的仿生促紅血球生成素和 ESA 的研究正在進行中，為市場提供了潛在的機會。具有成本效益的生物相似藥的開拓也為更廣泛的市場進入打開了大門，特別是在新興經濟體。然而，高製造成本、嚴格的監管途徑以及圍繞血栓栓塞事件和心血管風險的安全擔憂等挑戰正在限制市場成長。此外，來自替代療法的競爭和對患者特異性治療的需求是進一步的市場限制。

為了利用成長機會，公司應專注於加速長效 ESA 和個人化治療解決方案的研究。與醫療保健提供者合作進行臨床研究並利用人工智慧制定個人化治療策略可提供策略優勢。最佳化療效和病人依從性的給藥機制創新也是一個有前景的領域。 ESA 市場是一個動態市場，其特點是嚴格的法律規範和持續的科學探索，這表明公司應優先考慮合規性和適應性創新才能取得成功。隨著全球醫療保健系統轉向基於價值的護理，確保 ESA 的成本效益和有效性對於市場的永續性和擴張至關重要。

市場動態：快速發展的促紅血球生成素促效劑市場的關鍵市場洞察

供需的動態交互作用正在改變促紅血球生成素興奮劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球愛滋病毒、癌症和末期腎病 (ESRD) 發病率不斷上升
    • 由於重組 DNA 技術的改進，合成 ESRD 的發展加快
    • 政府積極努力擴大醫療基礎設施
  • 市場限制因素
    • 高成本EPO藥物
  • 市場機會
    • 新藥和具有成本效益的生物相似藥介紹
    • 創新分子開發的持續研發活動
  • 市場挑戰
    • 嚴格的藥品核准監理通訊協定

波特五力：引領促紅血球生成素興奮劑市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解促紅血球生成素興奮劑市場的外部影響

外部宏觀環境因素在塑造促紅血球生成興奮劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解促紅血球生成素興奮劑市場的競爭格局

對促紅血球生成素興奮劑市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣促紅血球生成素刺激器市場供應商的績效評估

FPNV定位矩陣是評估促紅血球生成素興奮劑市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製促紅血球生成素興奮劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對促紅血球生成素興奮劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球愛滋病毒、癌症和末期腎功能衰竭的發生率正在上升
      • 透過增強重組 DNA 技術促進 ESRD 合成形式的開發
      • 政府加強醫療基礎設施的有利舉措
    • 抑制因素
      • 昂貴的促紅血球生成素藥物
    • 機會
      • 新藥和具有成本效益的生物相似藥介紹
      • 持續的研發活動開發創新分子
    • 任務
      • 嚴格的藥品核准監理通訊協定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章促紅血球生成素興奮劑市場：依類型

  • Darbepoetin汀阿爾法
  • 阿爾法依泊汀
  • BETA-促紅血球生成素
  • 促紅血球Delta素δ
  • 依泊汀歐米茄

第7章促紅血球生成素興奮劑市場：依應用分類

  • 貧血
  • 抗逆轉濾病毒治療
  • 癌症化療
  • 腎臟疾病
  • 神經系統疾病
  • 腫瘤疾病
  • 傷口癒合

第8章美洲促紅血球生成素興奮劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區促紅血球生成素興奮劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲促紅血球生成素興奮劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Cipla Limited
  • Dr. Reddys Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Limited
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • LG Life Sciences Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-2D6687430059

The Erythropoietin Stimulating Agents Market was valued at USD 9.84 billion in 2023, expected to reach USD 10.32 billion in 2024, and is projected to grow at a CAGR of 5.64%, to USD 14.45 billion by 2030.

Erythropoietin Stimulating Agents (ESAs) are biologically engineered drugs used to promote red blood cell production, mainly for patients suffering from anemia due to chronic kidney disease, cancer treatments, or certain chronic conditions. These agents, including epoetin alfa and darbepoetin alfa, play a critical role in medical therapeutics by reducing the need for blood transfusions. The necessity and application of ESAs extend to the management of anemia in end-stage renal disease and are increasingly being explored in non-dialysis-dependent chronic kidney disease and other anemia-linked conditions. The market's end-use scope spans hospitals, clinics, and ambulatory surgical centers.

KEY MARKET STATISTICS
Base Year [2023] USD 9.84 billion
Estimated Year [2024] USD 10.32 billion
Forecast Year [2030] USD 14.45 billion
CAGR (%) 5.64%

Market growth is driven by the rising prevalence of chronic diseases, an aging population, and an increased demand for biologics. Furthermore, ongoing research into biomimetic erythropoietin and ESAs with improved efficiency and safety profiles presents potential opportunities in the market. The development of cost-effective biosimilars also opens avenues for broader market access, especially in emerging economies. However, challenges such as high production costs, stringent regulatory pathways, and safety concerns surrounding thromboembolic events and cardiovascular risks limit market growth. Additionally, competition from alternative therapies and the need for patient-specific treatments present further market constraints.

To harness growth opportunities, businesses should focus on advancing research into long-acting ESAs and individualized therapy solutions. Collaborations with healthcare providers for clinical research and leveraging artificial intelligence for personalized treatment strategies can provide strategic advantages. Innovating delivery mechanisms to optimize efficacy and patient compliance is also a promising area. The ESA market remains dynamic, characterized by stringent regulatory oversight and ongoing scientific exploration, suggesting that firms should prioritize compliance and adaptive innovation to succeed. As healthcare systems globally push towards value-based care, ensuring the cost-effectiveness and efficacy of ESAs will be crucial for market sustainability and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Erythropoietin Stimulating Agents Market

The Erythropoietin Stimulating Agents Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of HIV, cancer, and ESRD globally
    • Increasing development of synthetic forms of ESRD with enhanced recombinant DNA technology
    • Favorable government initiatives to increase healthcare infrastructures
  • Market Restraints
    • High cost EPO drugs
  • Market Opportunities
    • Introduction of novel drugs and cost-efficient biosimilar formulations
    • Ongoing robust research and development activities to develop innovative molecules
  • Market Challenges
    • Stringent regulatory protocols for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Erythropoietin Stimulating Agents Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Erythropoietin Stimulating Agents Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Erythropoietin Stimulating Agents Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Erythropoietin Stimulating Agents Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Erythropoietin Stimulating Agents Market

A detailed market share analysis in the Erythropoietin Stimulating Agents Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Erythropoietin Stimulating Agents Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Erythropoietin Stimulating Agents Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Erythropoietin Stimulating Agents Market

A strategic analysis of the Erythropoietin Stimulating Agents Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Erythropoietin Stimulating Agents Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Biocon Limited, Celltrion, Inc., Cipla Limited, Dr. Reddys Laboratories Ltd., F. Hoffmann-La Roche Ltd., Intas Pharmaceuticals Limited, Johnson & Johnson, Kyowa Kirin Co., Ltd., LG Life Sciences Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Erythropoietin Stimulating Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta, Epoetin-Delta, and Epoetin-Omega.
  • Based on Application, market is studied across Anemia, Antiretroviral Treatment, Cancer Chemotherapy, Kidney Disorders, Neural Disease, Oncology Diseases, and Wound Healing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of HIV, cancer, and ESRD globally
      • 5.1.1.2. Increasing development of synthetic forms of ESRD with enhanced recombinant DNA technology
      • 5.1.1.3. Favorable government initiatives to increase healthcare infrastructures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost EPO drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel drugs and cost-efficient biosimilar formulations
      • 5.1.3.2. Ongoing robust research and development activities to develop innovative molecules
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory protocols for drug approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Erythropoietin Stimulating Agents Market, by Type

  • 6.1. Introduction
  • 6.2. Darbepoetin Alfa
  • 6.3. Epoetin Alfa
  • 6.4. Epoetin Beta
  • 6.5. Epoetin-Delta
  • 6.6. Epoetin-Omega

7. Erythropoietin Stimulating Agents Market, by Application

  • 7.1. Introduction
  • 7.2. Anemia
  • 7.3. Antiretroviral Treatment
  • 7.4. Cancer Chemotherapy
  • 7.5. Kidney Disorders
  • 7.6. Neural Disease
  • 7.7. Oncology Diseases
  • 7.8. Wound Healing

8. Americas Erythropoietin Stimulating Agents Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Erythropoietin Stimulating Agents Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Erythropoietin Stimulating Agents Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Biocon Limited
  • 3. Celltrion, Inc.
  • 4. Cipla Limited
  • 5. Dr. Reddys Laboratories Ltd.
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Intas Pharmaceuticals Limited
  • 8. Johnson & Johnson
  • 9. Kyowa Kirin Co., Ltd.
  • 10. LG Life Sciences Ltd.
  • 11. Pfizer Inc.
  • 12. Sun Pharmaceutical Industries Ltd.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ERYTHROPOIETIN STIMULATING AGENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ERYTHROPOIETIN STIMULATING AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ERYTHROPOIETIN STIMULATING AGENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ERYTHROPOIETIN STIMULATING AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ERYTHROPOIETIN STIMULATING AGENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN-DELTA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY EPOETIN-OMEGA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY ANTIRETROVIRAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY CANCER CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY KIDNEY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY NEURAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY ONCOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM ERYTHROPOIETIN STIMULATING AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ERYTHROPOIETIN STIMULATING AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 108. ERYTHROPOIETIN STIMULATING AGENTS MARKET, FPNV POSITIONING MATRIX, 2023